Loading...
MNOV logo

MediciNova, Inc.NasdaqGM:MNOV Stock Report

Market Cap US$66.9m
Share Price
US$1.36
US$9
84.9% undervalued intrinsic discount
1Y-2.2%
7D-2.9%
1D
Portfolio Value
​
View

MediciNova, Inc.

NasdaqGM:MNOV Stock Report

Market Cap: US$66.9m

MediciNova (MNOV) Stock Overview

A biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. More details

MNOV fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Rewards

Earnings are forecast to grow 66.72% per year

Risk Analysis

Makes less than USD$1m in revenue ($597K)

Does not have a meaningful market cap ($67M)


MNOV Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

MediciNova, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for MediciNova
Historical stock prices
Current Share PriceUS$1.36
52 Week HighUS$1.96
52 Week LowUS$1.17
Beta0.63
1 Month Change-2.86%
3 Month Change-3.55%
1 Year Change-2.16%
3 Year Change-37.90%
5 Year Change-66.58%
Change since IPO-87.58%

Recent News & Updates

Recent updates

Analysis Article • Aug 28

Companies Like MediciNova (NASDAQ:MNOV) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Apr 19

We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysis Article • Nov 27

MediciNova (NASDAQ:MNOV) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Jul 11

We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Mar 18

Here's Why We're Not Too Worried About MediciNova's (NASDAQ:MNOV) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Oct 12

We Think MediciNova (NASDAQ:MNOV) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Sep 15

MediciNova to get US patent for MN-166 to treat brain cancer

MediciNova (NASDAQ:MNOV) said it will receive a new patent from the U.S. Patent and Trademark Office which covers MN-166 (ibudilast) to treat glioblastoma. The new patent is expected to expire no earlier than February 2039, the company said in a Sept. 14 press release. Glioblastoma is a type of cancer that can occur in the brain or spinal cord. The allowed claims cover a method of treating a patient with glioblastoma or recurrent glioblastoma wherein a patient expresses unmethylated MGMT, using MN-166 (ibudilast) in combination with one or more other therapeutic agents. "Results of our glioblastoma animal model study showed that median survival was longer in the group that received combination treatment with MN-166 plus temozolomide compared to the group that received the standard treatment of temozolomide alone," said MediciNova Chief Medical Officer Kazuko Matsuda.
Seeking Alpha • Aug 16

MediciNova's MN-166 to be part of study to treat Long COVID

MediciNova (NASDAQ:MNOV) said it plans to participate in a grant-funded clinical trial, dubbed RECLAIM, to evaluate MN-166 (ibudilast) and other therapies for treating Long COVID. The company added that it reached an agreement to collaborate with the University Health Network.
Seeking Alpha • Jul 22

MediciNova begins study of parenteral formulation of MN-166

MediciNova (NASDAQ:MNOV) said it started a first-in-human study of a new parenteral formulation of MN-166 (ibudilast). The company said the newly developed MN-166 (ibudilast) formulation will provide an additional option besides the current oral formulation. "With MN-166 expected to be effective to treat a variety of diseases, we believe expanding to a parenteral formulation increases the feasibility of treating more target indications, thus increasing the value of MN-166," said MediciNova Chief Medical Officer Kazuko Matsuda. In April, the company reported data from a phase 2 trial of MN-166 for alcohol use disorder, showing that the drug reduced alcohol craving on non-drinking days.
Seeking Alpha • Jun 30

MediciNova announces extension of BARDA contract for Ibudilast development

MediciNova (NASDAQ:MNOV) said on Wednesday that a modification to its contract with the Biomedical Advanced Research and Development Authority (BARDA) for its small molecule candidate MN-166 (ibudilast). Under the partnership with BARDA, the company will repurpose MN-166 as a potential medical countermeasure against chlorine gas-induced lung damage such as acute respiratory distress syndrome (ARDS) and acute lung injury (ALI). The contract was amended to extend the period of performance until March 2023. BARDA, a division of the U.S. Department of Health and Human Services will fund the proof-of-concept studies in preclinical models of chlorine gas-induced acute lung injury. The project has been funded in whole or in part with federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority. Last year in March, MediciNova jumps on BARDA partnership for Ibudilast development. Shares are up 2.75% after-hours.
Analysis Article • Mar 19

We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysis Article • Nov 23

MediciNova (NASDAQ:MNOV) Is In A Strong Position To Grow Its Business

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Aug 31

MediciNova: The Pain Of A Positive Outlook

MediciNova reported blasé Q2 2021 earnings on 08/12/2021. MediciNova's core pipeline consists of two candidate therapies being developed in treatment of eleven indications. MediciNova's MS program is a high potential, late stage program which has been in stall mode. MediciNova has operated under less financial strain than expected for a company with its advanced pipeline.
Seeking Alpha • Jun 21

MediciNova stock climbs 31% on positive MN-166 data in mid-stage alcohol use disorder study

MediciNova (MNOV) soars 30.6% premarket after announcing positive results from a Phase 2 trial of MN-166 (ibudilast) in alcohol use disorder ((AUD)), published in Nature’s Translational Psychiatry. The Phase 2 trial evaluated the effect of 14 days of ibudilast treatment on mood, heavy drinking, and neural reward signals in individuals with AUD. A total of 52 patients were enrolled. Key results include: Ibudilast did not have a significant effect on negative mood.Ibudilast, relative to placebo, reduced the odds of heavy drinking across time
Analysis Article • May 15

Companies Like MediciNova (NASDAQ:MNOV) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Shareholder Returns

MNOVUS BiotechsUS Market
7D-2.9%1.2%1.6%
1Y-2.2%35.9%28.5%

Return vs Industry: MNOV underperformed the US Biotechs industry which returned 35.9% over the past year.

Return vs Market: MNOV underperformed the US Market which returned 28.5% over the past year.

Price Volatility

Is MNOV's price volatile compared to industry and market?
MNOV volatility
MNOV Average Weekly Movement6.9%
Biotechs Industry Average Movement10.8%
Market Average Movement7.2%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.0%

Stable Share Price: MNOV has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: MNOV's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20006Yuichi Iwakimedicinova.com

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute respiratory distress syndrome. The company is also developing MN-001 (tipelukast), an orally bioavailable small molecule compound in Phase 2 clinical trial to treat fibrotic and other metabolic disorders, including nonalcoholic fatty liver disease and hypertriglycedemia.

MediciNova, Inc. Fundamentals Summary

How do MediciNova's earnings and revenue compare to its market cap?
MNOV fundamental statistics
Market capUS$66.94m
Earnings (TTM)-US$11.72m
Revenue (TTM)US$596.64k
112.2x
P/S Ratio
-5.7x
P/E Ratio

Is MNOV overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
MNOV income statement (TTM)
RevenueUS$596.64k
Cost of RevenueUS$548.71k
Gross ProfitUS$47.93k
Other ExpensesUS$11.77m
Earnings-US$11.72m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)-0.24
Gross Margin8.03%
Net Profit Margin-1,964.35%
Debt/Equity Ratio0%

How did MNOV perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/31 13:24
End of Day Share Price 2026/05/29 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

MediciNova, Inc. is covered by 8 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason KolbertD. Boral Capital LLC.
Lander Egaña-GorroñoH.C. Wainwright & Co.
Elemer PirosLucid Capital Markets